Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another class of complement targeted therapeutics have recently been approved. Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/AMY-101)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamers, Christina, Xue, Xiaoguang, Smieško, Martin, van Son, Henri, Wagner, Bea, Berger, Nadja, Sfyroera, Georgia, Gros, Piet, Lambris, John D., Ricklin, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488889/
https://www.ncbi.nlm.nih.gov/pubmed/36127336
http://dx.doi.org/10.1038/s41467-022-33003-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488889/
https://www.ncbi.nlm.nih.gov/pubmed/36127336
http://dx.doi.org/10.1038/s41467-022-33003-7

Ejemplares similares